ArticleGeneral thoracic and cardiovascular surgery2026
Pulmonary metastasectomy for malignant melanoma prolongs survival significantly compared to non-surgical therapy.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPulmonary metastasectomy (PM) is an established treatment for selected patients with pulmonary metastases. While systemic therapies such as immune checkpoint inhibitors, and stereotactic radiation have become standard for unresectable or metastasized melanoma patients, no randomized controlled trials directly assess the benefit of PM by itself in oligometastatic melanoma patients with lung metastases. This retrospective study compares long-term survival outcomes in patients undergoing PM versus those receiving non-surgical therapy for pulmonary metastatic melanoma.
methodsWe retrospectively analyzed melanoma patients from the skin cancer center Cologne who were treated with curative intent for their primary tumor and later developed isolated pulmonary metastases. Patients in the non-surgical group had biopsy-confirmed lung metastases. Survival outcomes between patients undergoing PM and those receiving non-surgical therapies were compared.
resultsBetween 2012 and 2020, 87 patients met the inclusion criteria: 49 underwent PM and 38 received non-surgical therapy. The number of pulmonary metastases differed significantly between groups (1.27 ± 0.57 vs. 3.2 ± 1.1; p < 0.001). BRAF-mutations were more common in the non-surgical group (35.4% vs. 55.3%; p = 0.04). Patients undergoing PM showed significantly improved 3-year (88.0% vs. 65.7%; p = 0.04) and 5-year survival rates (81.3% vs. 30.8%; p = 0.002) compared to the non-surgical group. Kaplan-Meier analysis confirmed prolonged overall survival in the PM group (log-rank p < 0.02). However, among patients with BRAF mutations, survival did not differ significantly between the groups (p = 0.09).
conclusionsPM is associated with favorable overall survival. These findings support considering PM as a treatment option in selected patients to improve long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.